… treatment in patients with colchicine-resistant FMF. However, … studies have shown that
anakinra and canakinumab may be … trial has confirmed the efficacy and safety of canakinumab in …

… The efficacy and safety of canakinumab on colchicine-resistant patients is less known …
colchicine resistant. Patients with persistent arthritis were treated with methotrexate and etanercept …

… Familial Mediterranean Fever (FMF) is the most common … and/or canakinumab Patients were
started Anakinra only when … To the best of our knowledge, this study provides efficacy and …

… of colchicine-resistant FMF patients (evidence 1B) [50]. TNF inhibitors have also been tested
in colchicine-resistant … molecule (ie, anakinra) in order to test effectiveness. Medium or long …

… defined an adolescent, with recurrent fever and abdominal … A RCT, which included 24
colchicine-resistant FMF (crFMF) … ), with a good safety profile on the anakinra arm [154]. Recently …

… the efficacy of biologic therapy in colchicine-resistant or -intolerant patients with FMF. …
efficacy of TNF inhibitors including etanercept, infliximab and adalimumab in colchicine-resistant …

… To study current knowledge on anakinra treatment for FMF, … “familial Mediterranean fever”
crossed with the term “anakinra” … efficacy and safety of canakinumab for colchicine resistant …

… Recurrent self-limited attacks of fever and short-lived inflammation in the serosal membranes,
joints, and skin are the leading features of familial Mediterranean fever (FMF), the most …

… high rate of incompliance with colchicine especially among adolescent patient (17). Thus, in
… In addition, anakinra has been used successfully in two patients with PFMS associated with …

… Colchicine resistant was defined as more than one attack per … Anakinra was given 100 mg
daily and canakinumab was given … of activity of FMF and efficacy of treatments. Most widely …